search
Back to results

Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria

Primary Purpose

Cerebral Malaria

Status
Unknown status
Phase
Phase 3
Locations
Uganda
Study Type
Interventional
Intervention
Intrarectal quinine
Sponsored by
Makerere University
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cerebral Malaria focused on measuring Cerebral, malaria, intra-rectal, quinine, children, Uganda, efficacy, safety

Eligibility Criteria

6 Months - 5 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Children aged 6 months to 5 years admitted to Mulago hospital during the study period who satisfy the World Health Organization (WHO) case definition of cerebral malaria (Unarousable coma lasting more than 30 minutes after a seizure, with peripheral asexual P.falciparum parasitaemia and absence of other causes of coma) and whose caretakers give informed consent. Exclusion Criteria: Patients with diarrhea (more than 4 motions/24 hours) Any recent anal pathology (such as rectal bleeding, rectal prolapse) Documented quinine treatment in previous 48 hours.

Sites / Locations

  • Mulago Hospital

Outcomes

Primary Outcome Measures

Parasite clearance time

Secondary Outcome Measures

Fever clearance time
Coma recovery time
Time to sit unsupported
Time to begin oral intake
Mortality
Neurological sequelae
Adverse drug events

Full Information

First Posted
July 26, 2005
Last Updated
August 3, 2005
Sponsor
Makerere University
Collaborators
Sanofi-Synthelabo, Ministry of Health, Uganda
search

1. Study Identification

Unique Protocol Identification Number
NCT00124267
Brief Title
Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria
Official Title
Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria: a Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2005
Overall Recruitment Status
Unknown status
Study Start Date
September 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
January 2004 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Makerere University
Collaborators
Sanofi-Synthelabo, Ministry of Health, Uganda

4. Oversight

5. Study Description

Brief Summary
Cerebral malaria is the most lethal complication of P.falciparum infection with a mortality rate between 5 and 40%. Intravenous quinine remains the recommended treatment for cerebral malaria. However its administration is often not feasible due to lack of simple equipment or trained staff. When referral is not possible, a viable alternative is needed. The intrarectal route is of interest in children since it is painless and simple. Studies of the efficacy of intrarectal quinine in the treatment of cerebral malaria are limited. The study aims to establish the efficacy of intrarectal quinine in the treatment of childhood cerebral malaria.
Detailed Description
Cerebral malaria is the most lethal complication of P.falciparum infection with a mortality rate between 5 and 40%. Intravenous quinine remains the recommended treatment for cerebral malaria. However its administration is often not feasible due to lack of simple equipment or trained staff. When referral is not possible, a viable alternative is needed. The intrarectal route is of interest in children since it is painless and simple. A few studies in Francophone Africa have reported clinical efficacy and tolerance of intrarectal quinine. Although the studies were randomized trials, they were not blinded and did not use the WHO definition of cerebral malaria as selection criteria. The current study aims to establish whether intrarectal quinine is as effective and as safe as intravenous quinine in the treatment of childhood cerebral malaria. To address the shortcomings of the Francophone African studies, the investigators have designed a randomized, double blind placebo controlled clinical trial to include patients who meet the WHO definition of cerebral malaria. Hypothesis: Intrarectal quinine (15mg/kg every 8 hours) given to children with cerebral malaria, will lead to a shorter parasite clearance time (39.9 hours) than intravenous quinine (55.0 hours). The investigators calculated a sample size of 54 patients in each group for 90% power and 95% confidence. In the calculation, the researchers assumed that the children receiving intrarectal quinine would have a mean parasite clearance time of 39.9 (SD 24.3) hours and those receiving intravenous quinine would have a mean parasite clearance time of 55.0(SD 24.3) hours (27.5% effect size), according to a study by Aceng, Byarugaba and Tumwine in the same hospital.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cerebral Malaria
Keywords
Cerebral, malaria, intra-rectal, quinine, children, Uganda, efficacy, safety

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
108 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Intrarectal quinine
Primary Outcome Measure Information:
Title
Parasite clearance time
Secondary Outcome Measure Information:
Title
Fever clearance time
Title
Coma recovery time
Title
Time to sit unsupported
Title
Time to begin oral intake
Title
Mortality
Title
Neurological sequelae
Title
Adverse drug events

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
5 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children aged 6 months to 5 years admitted to Mulago hospital during the study period who satisfy the World Health Organization (WHO) case definition of cerebral malaria (Unarousable coma lasting more than 30 minutes after a seizure, with peripheral asexual P.falciparum parasitaemia and absence of other causes of coma) and whose caretakers give informed consent. Exclusion Criteria: Patients with diarrhea (more than 4 motions/24 hours) Any recent anal pathology (such as rectal bleeding, rectal prolapse) Documented quinine treatment in previous 48 hours.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jane Achan, MBChB
Organizational Affiliation
Department of Paediatrics and Child Health, Makerere University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mulago Hospital
City
Kampala
ZIP/Postal Code
7051
Country
Uganda

12. IPD Sharing Statement

Citations:
PubMed Identifier
15504872
Citation
Pussard E, Straczek C, Kabore I, Bicaba A, Balima-Koussoube T, Bouree P, Barennes H. Dose-dependent resorption of quinine after intrarectal administration to children with moderate Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2004 Nov;48(11):4422-6. doi: 10.1128/AAC.48.11.4422-4426.2004.
Results Reference
background
PubMed Identifier
12610739
Citation
Barennes H, Sterlingot H, Nagot N, Meda H, Kabore M, Sanou M, Nacro B, Bouree P, Pussard E. Intrarectal pharmacokinetics of two formulations of quinine in children with falciparum malaria. Eur J Clin Pharmacol. 2003 Feb;58(10):649-52. doi: 10.1007/s00228-002-0546-2. Epub 2003 Jan 29.
Results Reference
background
PubMed Identifier
9850403
Citation
Barennes H, Munjakazi J, Verdier F, Clavier F, Pussard E. An open randomized clinical study of intrarectal versus infused Quinimax for the treatment of childhood cerebral malaria in Niger. Trans R Soc Trop Med Hyg. 1998 Jul-Aug;92(4):437-40. doi: 10.1016/s0035-9203(98)91083-5.
Results Reference
background
PubMed Identifier
15705690
Citation
Aceng JR, Byarugaba JS, Tumwine JK. Rectal artemether versus intravenous quinine for the treatment of cerebral malaria in children in Uganda: randomised clinical trial. BMJ. 2005 Feb 12;330(7487):334. doi: 10.1136/bmj.330.7487.334.
Results Reference
background
PubMed Identifier
12973645
Citation
Simoes EA, Peterson S, Gamatie Y, Kisanga FS, Mukasa G, Nsungwa-Sabiiti J, Were MW, Weber MW. Management of severely ill children at first-level health facilities in sub-Saharan Africa when referral is difficult. Bull World Health Organ. 2003;81(7):522-31. Epub 2003 Sep 3.
Results Reference
background
PubMed Identifier
19852829
Citation
Nakibuuka V, Ndeezi G, Nakiboneka D, Ndugwa CM, Tumwine JK. Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial. Malar J. 2009 Oct 24;8:237. doi: 10.1186/1475-2875-8-237.
Results Reference
derived

Learn more about this trial

Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria

We'll reach out to this number within 24 hrs